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Manuscript 18-0339 Revision 2 
Cronin et al 
Responses to reviewers (2) 
 
Editor 
1. Bruyn’s 1968 review of 150 cases 
 
We have added specific reference to this review of cases in the Introduction 
Reviewer 1 
2. Usage of the terms ‘symptoms’ and ‘signs’ 
We agree that the discrimination of these terms requires more clarity. It is particularly relevant 
when discussing JHD as children may lack the ability to report on their symptoms making clinical 
examination findings (ie signs) even more important. We have amended the manuscript where 
appropriate to include terms such as ‘symptoms and signs’; ‘symptoms or signs’ or ‘clinical 
features’ instead of just ‘symptoms’.  
 
  
2 
 
Clinical presentation and features of Juvenile-onset Huntington's disease: a systematic 
review 
 
Thomas Cronina,c, Anne Rosserb,c,d, Thomas Masseyc,d * 
 
a Institute of Neuroscience, Newcastle University, Newcastle, UK 
b Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, UK 
c MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine 
and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK 
d Brain Research And Intracranial Neurotherapeutics (BRAIN) unit 
 
* Correspondence to: Thomas Massey, MRC Centre for Neuropsychiatric Genetics and Genomics, 
Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ, UK. Tel.: +44 2920 688353; E-mail: 
MasseyT1@cardiff.ac.uk. 
 
 
 
3 
 
Abstract 
BACKGROUND: Juvenile-onset Huntington’s disease (JHD) is defined by onset at the age of 20 
or younger and represents approximately 5% of all HD cases. Patients with JHD present with a 
broad range of symptoms and signs that only overlap partially with adult-onset HD. A greater 
awareness and understanding of the presentation of JHD would improve the diagnosis and treatment 
of this condition. 
 
OBJECTIVE: To undertake a systematic review of the literature relating to the clinical features at 
first presentation of JHD. 
 
METHODS: We searched MEDLINE and EMBASE for all studies describing presenting features 
of JHD patients, performed quality control, and collated and analysed the data.  
 
RESULTS: We screened 2917 records for eligibility, and included 79 studies (n=285 individuals) 
in the analysis. All were case reports and case series, synthesising data from 25 different countries. 
Thirty-four different clinical features at presentation were identified. Four groups of symptoms or 
signs were present in more than 15% of cases: behavioural disturbance, falls/gait disturbance, 
cognitive impairment and parkinsonian features. Where data were available, the median age of onset 
was 9 years, 52% were female, the mutant HTT allele was transmitted paternally in 80% of cases, 
and the median CAG repeat length was 64.  
 
CONCLUSIONS: JHD can present with a wide variety of symptoms and signs, with non-motor 
characteristics being observed most frequently. Greater recognition of these presentations will 
facilitate early diagnosis and management. Tailored rating scales to score motor, non-motor, and 
functional impairments specifically in JHD are required to standardise research studies, and are 
under development. 
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Introduction 
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder that affects 
approximately 1 in 8,000 people in Western populations [1]. Symptoms typically start between the 
ages of 40 and 60, although there is considerable variation. Patients with HD develop a mixture of 
involuntary movements, psychiatric and behavioural problems, and cognitive impairment and these 
typically progress over 10-30 years with resultant morbidity and mortality [2]. A small proportion 
of HD patients (approximately 5%, but variable depending on population [3]) develop clinical 
features before the age of 20: they have been conventionally defined as having Juvenile-onset HD 
(JHD) based on a review of 150 cases by Bruyn in 1968 [4]. Since a number of studies in recent 
years have also included onset at 20 years as JHD, we have used a definition of JHD as onset at 20 
years or younger here. JHD cases have been further arbitrarily subdivided into childhood-onset (at 
or before 10 years of age) and adolescent-onset (between 11 and 20 years of age) in some reports 
to facilitate analyses of age-relevant factors [5]. Approximately 20% of JHD cases have onset in 
childhood [3]. It is worth noting that the use of ‘Juvenile-onset’ as a classifier is under review and 
is likely to be replaced in the future by ‘Paediatric HD’ for gene-positive individuals manifesting 
disease under the age of 18, rather than defining a group of individuals according to an arbitrary 
age at onset. 
 
Although adult-onset HD and JHD patients share the same causative mutation (an expanded tract 
of at least 36 tandem CAG repeats in exon 1 of the HTT gene), and despite the age-based distinction 
being arbitrary, there are significant phenotypic differences between the two patient cohorts [6]. 
Most descriptions of JHD feature a parkinsonian syndrome of rigidity, dystonia and bradykinesia, 
compared to the chorea typically associated with adult-onset HD. In addition, JHD cases may also 
feature cerebellar signs and epilepsy, as well as behavioural problems and developmental delay [6]. 
This broad phenotypic range has considerable overlap with many other 
neurodevelopmental/neurodegenerative disorders that can present in childhood, such as 
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mitochondrial diseases, epilepsies, Wilson’s disease, some spinocerebellar ataxias (e.g. SCA2, 
SCA3, SCA17), dentatorubral-pallidoluysian atrophy (DRPLA), and juvenile-onset Parkinson’s 
disease, leading to delays in accurate diagnosis as well as inadequate genetic counselling and 
treatment [7]. 
 
JHD is a rare disorder, affecting approximately 1 in 200,000, and consequently the published 
literature on clinical manifestations of JHD is limited to case reports and a few small case-series. In 
order to improve awareness and understanding of the diverse initial presentations of JHD we have 
systematically identified and collated all the existing published data on presenting features and 
patient characteristics. We have also assessed whether there are significant correlations between 
CAG repeat length, age at clinical onset and clinical presentation in our combined dataset. 
 
Materials and Methods 
No specific published protocol was used for this review. 
 
Search strategy 
A search strategy was developed to identify all articles in MEDLINE and EMBASE. Scoping 
searches were carried out beforehand to refine the search terms and ensure that relevant studies 
were obtained. The search terms used in the ‘abstract’ and ‘title’ fields were Huntington* AND 
juvenile OR child* OR early* OR young* OR paediatric OR Westphal OR infant* (*indicates 
searches including unlimited truncations of the target word). The database was searched from 
January 1969 (when JHD was defined by Bruyn [4]) to May 2017. References were exported to the 
reference management software Mendeley Desktop v1.17.10. Duplicates were removed and non-
English language studies were excluded.  
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Further hand searches were performed through screening the bibliographies of full-text records that 
were accessed, and using the Google Scholar ‘cited by’ feature to find articles that had cited these 
publications.  
 
Study selection 
Titles and abstracts were screened and only primary research studies reporting on the initial 
presenting clinical features of JHD were considered for selection. Any study design was accepted. 
Studies that selected cases based on the presence of specific clinical manifestations but not 
necessarily at presentation (e.g. seizures) were not included to avoid giving disproportionate weight 
to those features in the data synthesis. Studies were also excluded if data were reported on both 
adults and children and it was not possible to extract the juvenile case data. In addition, studies that 
reported on published data from other papers already included in the analysis were also excluded.  
 
Quality assessment 
Once a short-list of eligible studies for potential inclusion had been assembled, one reviewer 
assessed the quality of these studies. These were all case series and case reports. There is no 
universally accepted tool for evaluating the quality of such studies. Therefore, matrices for assessing 
the quality of case series and case reports were developed from recommendations using several 
sources [8-11], including the National Institutes of Health (NIH) and The Joanna Briggs Institute 
(JBI). Quality was assessed across eight domains for case series: methodology, description of 
demographics, whether multi-centred, clear inclusion/exclusion criteria, consecutive recruitment, 
clear clinical information, clear outcomes reported, appropriate statistics. Case series that received 
unsatisfactory ratings in fewer than four domains were included in this review (supplementary 
material Table S1). Quality was assessed across five domains for case reports: description of 
demographics, clear patient history, clear clinical information, appropriate diagnostic 
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tests/assessment methods, clear outcomes reported. Case reports that received unsatisfactory ratings 
in fewer than three domains were included in this review (supplementary material Table S2). 
 
Data extraction 
Data were extracted from the selected studies by one review. Studies were divided into ‘aggregated 
data studies’ (case series reporting data aggregated for all patients) and ‘individual data studies’ 
(case series and case reports reporting data for separate patients). The following were extracted 
from all studies: lead author, year of publication, country of study, study design and sample size. 
Sex, mode of transmission, age at onset, and CAG repeat length were also extracted where possible. 
In ‘aggregated data studies’ the raw data were extracted whenever possible.  
 
For ‘individual data studies’, data on presenting features or features were extracted using a coding 
system developed from prior interrogation of the literature. For instance, features that were 
considered similar were combined (e.g. ‘seizures’ and ‘epilepsy’ were combined into a single 
category: ‘seizures’). Within case series, data from individuals could usually be extracted. If not, 
aggregated data referring to presenting features were utilised where clear. 
 
Data analysis 
Characteristics of reported cases and their described clinical manifestations were summarised as 
percentages. Age at onset of symptoms or signs was extracted where possible, and median values 
calculated. CAG repeat lengths were noted when available. In two studies with aggregated data 
individual ages at onset and CAG repeats were not reported: these were omitted from the analysis. 
Statistical analyses consisted of Pearson’s correlation coefficient to investigate the association 
between CAG repeat length and age at onset of symptoms or signs, Fisher’s exact test to compare 
age of onset, and binomial distribution to compare differences between males and females, as well 
as paternal and maternal transmission. 
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Results 
Literature search and case selection 
The search strategy and decision tree are shown in Fig. 1. A total of 2917 articles were screened by 
title and abstract. 2815 studies were excluded for a variety of reasons including being reviews and 
not containing data relevant to the research question. The remaining 102 articles were screened by 
full-text. A further 23 articles were excluded for various reasons: being unrelated to the research 
question, having unextractable JHD data, not being primary research, focussing on one clinical 
manifestation of JHD, presenting data previously published elsewhere, or not meeting the quality 
criteria. This left a total of 79 studies eligible for analysis (supplementary material references).  
 
The 79 studies included in our analysis here comprised 69 case reports and 10 case series (the largest 
having 30 cases) and yielded a total sample size of 285 cases of JHD. Studies were conducted in 25 
countries and included some from Europe, Asia, North and South America, and South Africa. We 
were able to extract at least partial data on sex, mode of transmission, age at onset, and CAG repeat 
length for 229 individual JHD cases out of the total number of 285. The remaining 56 cases were 
described in larger case series with data presented as pooled results: this prevented extraction of 
individual case data for our analyses. 
 
Demographics, inheritance and CAG repeat lengths of JHD cases 
The sex of individuals with JHD could be ascertained in 189 cases. There was no significant 
difference between the numbers of affected males and females (Figure 2A; 92 males, 97 females; p 
= 0.32), and this was also true in the childhood and adolescent onset subgroups (Figure 2B). 
However, almost 80% of JHD patients inherited the disease-causing HTT allele from their father, 
in keeping with known increased genetic anticipation through the paternal line (Figure 2A; 166 
paternally inherited, 42 maternally inherited; p = 0.0001). A slightly greater proportion of 
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childhood-onset cases were inherited paternally compared with adolescent-onset cases (Figure 2B; 
87.0% and 72.7% respectively; p = 0.02). The age at onset of first symptoms or signs was 
individually reported for 228 cases and ranged from age 1 to 20 with a median age at onset of 9 
years (Figure 2C). A total of 127 cases (56%) had childhood onset (between ages 0-10 inclusive) 
and 101 (44%) had adolescent onset (age 11-20).  
 
The age at onset of clinical features and the CAG repeat length were both reported for 154 JHD 
cases. The median CAG repeat length was 64 repeats, but there was a wide range of 39 to 265 
repeats (Figure 2D). As expected, there was a significant inverse relationship between CAG repeat 
length and age at onset of clinical symptoms or signs (Pearson’s correlation coefficient -0.56, p < 
0.00001), although this correlation was weaker at longer repeat lengths. Interestingly, cases of JHD 
presenting between age 11 and 20 had CAG repeat lengths almost exclusively between 39 and 75 
(excepting one case of an 11 year old with 92 repeats), whereas there was a much broader range of 
repeat length in those cases of JHD presenting between age 1 and 10 (41-265 CAG repeats). Many 
of the younger presentations up to the age of 10 had much longer CAG tracts, often over 100 repeats 
(Figure 2D).  
 
Features of JHD at first presentation 
A wide range of different presenting features were reported in the 285 JHD cases analysed here 
(Table 1). In total, 34 different presenting features were identified, and these were grouped into 
categories of related features to facilitate analysis. For example, ‘seizures’ and ‘epilepsy’ were 
grouped together, as were ‘rigidity’, ‘bradykinesia’ and ‘parkinsonism’ (Table 1). Seven clinical 
presentations occurred in at least 10% of cases: behavioural disturbance/personality change (26%), 
falls/gait disturbance (14%), cognitive decline/memory impairment (18%), features of 
parkinsonism (16%), chorea (12%), declining school performance (12%), and speech 
disturbance/dysarthria (12%). We were able to extract data pertaining to 229 individual cases, with 
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the remaining information coming from grouped case series. A single clinical feature was reported 
at presentation for over half of the JHD cases collated here (131/229 cases, 57%). The remaining 
98 patients each displayed more than one clinical feature at presentation: 55/229 (24%) reported 
two features, 32/229 (14%) reported three features, and 11/229 (5%) reported four features. 
Presenting features were also investigated by age at onset, comparing the childhood (0-10 years) 
and adolescent (11-20 years) ranges.  This analysis was possible only for the 228 individuals where 
data could be extracted. There were significant differences in the frequencies of particular 
presenting features in the two age groups (Table 1): falls/gait disturbance, speech disturbance, 
seizures, and developmental delay/regression were all more common in the childhood-onset cases, 
whereas fine motor disturbance, depression/suicidal ideation and behavioural/personality change 
were all more common in the older, adolescent-onset cases. 
Discussion 
This systematic review of the presenting features of JHD is the largest to date, collating data from 
285 individual cases reported in 79 studies from 25 countries over more than 40 years. Although 
not all studies reported complete datasets, overall there were sufficient numbers to allow analysis.  
Over half of the JHD cases included here reported childhood onset of disease before the age of 11, 
contrasting with previously published population estimates of just 20% [3]. The range and balance 
of presenting symptoms and signs described here likely reflects this distribution of cases. A cross-
sectional analysis of 1766 HD patients in the European HD REGISTRY showed that over 67% had 
motor problems (mostly chorea) at presentation, while 22% and 9% had psychiatric and cognitive 
presentations, respectively. Since just 2.1% of these cases were classified as JHD, this range of 
presenting features mainly represents adult-onset disease [12]. These findings contrast with the JHD 
presentations collated here. Whilst presentation with motor symptoms or signs was still common in 
JHD (approximately 50% of cases), only 12% had chorea and there was a similar prevalence of a 
rigid, bradykinetic, parkinsonian phenotype (Table 1). These figures are broadly similar to those 
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reported elsewhere for motor phenotypes in all JHD (not just presentation) where all patients had a 
motor phenotype of some sort: approximately 60% were mainly rigid and 40% mainly choreic 
[13,14]. The parkinsonian motor phenotype is rare in adulthood, although such features may 
develop later in the disease course [6]. Although there is increasing recognition of early cognitive 
and psychiatric problems in adult-onset HD, they remain more prevalent in JHD: presentation with 
behavioural disturbances, cognitive impairment, learning difficulties at school and developmental 
regression were all frequently reported (Table 1). 
Very early, childhood JHD (age 0-10) is characterised by neurodevelopmental as well as 
neurodegenerative pathology. For example, seizures, developmental delay or regression, falls/gait 
problems, and speech disturbance are all particularly prevalent in this age group. Seizures are 
reported at presentation in approximately 15% of childhood JHD cases here, in contrast to a 
previous study that found them to be rare [15]. Overall they have been reported in up to a third of 
JHD cases, sometimes developing later in the disease course [14,15]. Given that seizures occur in 
up to 0.5% children in the general population, it can be difficult for clinicians to diagnose JHD on 
the basis of seizures alone. Similar problems arise when considering other neurodevelopmental 
phenotypes, all of which are not specific for HD and have a broad differential diagnosis, particularly 
in the absence of a family history of HD. The older age group of adolescent-onset JHD (age 11-20) 
display more features of adult-onset HD, such as motor impairment and psychiatric pathologies, 
although non-motor features remain common, in agreement with prior studies [13]. 
There are unavoidable biases and limitations in this study: data collection was retrospective; 
methodologies were heterogeneous; only cases, and not controls, were reported; inconsistent and 
ambiguous language was often used in reporting, and different terms relating to specific symptoms 
and signs were used in different studies, making collation of data difficult (e.g. ‘ataxia’, ‘imbalance’, 
‘unsteadiness’ and ‘gait imbalance’ may all refer to the same feature, but combining them in the 
analysis makes the assumption that they do). Furthermore, given that we have included studies from 
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before 1993 when genetic diagnosis became widely available, we do not have definitive genetic 
evidence of JHD in all cases. Historically, a lack of awareness of JHD might have led to the earliest 
presenting symptoms or signs being missed and some patients with adolescent-onset but adult 
diagnosis not being recorded as JHD. A further bias against reporting of adolescent-onset JHD 
comes from publication of younger-onset cases that are sometimes perceived as more unusual and 
interesting. Lastly, some phenotypic features such as depression and behavioural/personality 
problems are particularly difficult to diagnose in younger age-groups and so there might be an 
inherent bias towards their reporting in the adolescent-onset group.  
CAG repeat lengths showed the expected inverse relationship with age at onset of disease, although 
there was considerable variation (Fig. 2B). Onset of JHD in childhood (0-10 years of age) was 
particularly variable, associated with CAG repeat lengths ranging from 41 to 265, the majority (59%) 
having over 80 repeats. Onset of JHD in adolescence (11-20 years of age) was associated with a 
tighter range of 39-75 CAGs, although there was still considerable variation in CAG repeat length 
between people with the same age at onset. This variability likely reflects the influence of modifier 
genes and environmental factors that can affect the pathogenesis of an expanded CAG repeat in 
cells [16]. In addition, technical developments in CAG repeat assays over the last 25 years mean 
that contemporary reporting of long repeat lengths is likely to be much more accurate than that from 
early genetic studies in the 1990s. We did not have adequate numbers to test the association of CAG 
repeat length with clinical features of JHD at presentation. Significantly more cases of JHD were 
inherited paternally than maternally, especially those with earlier onset, in agreement with several 
previous studies (summarised in [4]). However, it is important to note that JHD can also arise 
through the maternal line. 
A recent retrospective analysis of 36 JHD patients from Italy and Argentina divided them by CAG 
repeat length into highly expanded (>80 CAG) or low expansion (<80 CAG) groups and showed 
that the former group presented at a younger age and tended to progress more rapidly. The highly 
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expanded group often presented with gait disturbance and/or neurodevelopmental phenotypes in 
contrast to the low expansion group where loss of hand dexterity was most common [17]. These 
findings corroborate the trends described in this systematic review. 
Implications for practice 
The data in this review reinforce the knowledge that JHD can present with a mixture of both motor 
and non-motor symptoms and signs, many of which are found in a range of neurodevelopmental 
paediatric diseases and not solely JHD. These porblems can affect a wide range of functions and 
require input from a multidisciplinary team for effective management. It has been shown previously 
that the exact presenting phenotype of HD is a poor predictor of a positive gene test for HD and that 
a family history of HD is the most useful indicator [18]. Current clinical guidance is not to test 
unaffected at-risk children under the age of 18 for the HD mutation unless the child, usually an 
older adolescent, specifically requests the test and engages with a period of genetic counselling 
beforehand [19]. Children with symptoms or signs consistent with JHD under the age of 18 may 
have a diagnostic HD gene test. Often this will be in the context of a family history of HD, but there 
are two groups of affected children without a known family history who might be diagnosed with 
JHD during clinical work-up. First, genetic anticipation means that a child may present with features 
of JHD before anyone else in their family, even if a family history were later to emerge. There are 
a number of case reports of this situation in the literature [20,21] and it is common in other diseases 
caused by expanded repeats such as myotonic dystrophy. Clearly a diagnosis of JHD would then 
have implications for older generations and so careful discussion with parents should be undertaken 
before testing. Second, true de novo mutations can arise at a low rate (approximately 10% of all HD 
cases), usually from expansion of an intermediate range CAG repeat allele (27-35 repeats) in a 
parent into the disease-causing range in the child. Therefore, JHD should be considered in children 
with an undiagnosed neurodevelopmental and/or motor syndrome and no family history of HD.   
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Finally, there is still a lack of clinical tools for assessing and monitoring JHD. Adult HD is followed 
in longitudinal studies such as Registry-HD and Enroll-HD using scoring systems for motor 
(Unified HD Rating Scale (UHDRS) motor), behavioural (Problem Behaviours Assessment, PBA) 
and functional (UHDRS Total Functional Capacity, Functional Assessment, and Independence 
Scale) abilities. These assessments all require reasonable (adult) cognitive abilities, such as the 
ability to follow instructions, and ask questions about occupation, finances, driving, and everyday 
living that are specifically framed for the adult patient. These tools have been modified for use in 
paediatric populations, but the low prevalence of JHD means that validation of these adapted scales 
is still lacking [22,23]. Tailored clinical JHD assessments, based on the broader and phenotypically 
different presentations illustrated here, will improve our understanding of this rare condition and be 
central to longitudinal observations both in disease natural history studies and clinical trials. These 
tools are being developed by the European HD network working group on JHD. This working group 
is also discussing a change in nomenclature from JHD to ‘paediatric HD’, defined as clinical onset 
of HD before the age of 18.  In addition, if disease-modifying therapies for HD emerge over the 
next few years, then early treatment to prevent neuronal loss will be central to disease management, 
and the advice against testing for JHD in unaffected at-risk children may need to be revisited. 
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Tables 
Table 1. Clinical characteristics of JHD patients at first presentation, grouped by similarity and 
ranked by frequency in the collated JHD population of 285 individuals.  
Clinical characteristics All cases 
(0-20 y; n=285) 
 
No./Total No. (%) 
 
Childhood onset 
(0-10 y; n=127) 
 
No./Total No. (%) 
Adolescent onset 
(11-20 y; n=101) 
 
No./Total No. (%) 
p value 
Behavioural disturbance/ personality change 75/285 (26.3) 25/127 (19.7) 30/101 (29.7) > 0.05 
Falls/ gait disturbance/ ataxia/ cerebellar signs/ 
imbalance/ unsteadiness 
60/285 (21.1) 46/127 (36.2) 9/101 (8.9) 0.0001 
Cognitive/ memory impairment  51/285 (17.8) 17/127 (13.4) 17/101 (16.8) > 0.05 
Rigidity/ bradykinesia/ parkinsonism 41/285 (14.3) 22/127 (17.3) 17/101 (16.8) > 0.05 
Chorea 35/285 (12.3) 9/127 (7.1) 10/101 (9.9) > 0.05 
Declining school performance 35/285 (12.3) 18/127 (14.1) 17/101 (16.8) > 0.05 
Speech disturbance/ dysarthria  35/285 (12.3) 23/127 (18.1) 6/101 (5.9) 0.008 
Seizures 26/285 (9.1) 19/127 (15.0) 2/101 (1.9) 0.0008 
Other movement disorder (including dystonia/ tics/ 
shoulder twitching/jerking / action myoclonus/ 
excessive blinking) 
20/285 (7.0) 12/127 (9.4) 7/101 (6.9) > 0.05 
Developmental regression/delay 17/285 (6.0) 17/127 (13.4) 0/101 (0) 0.0001 
Depression/ suicidal ideation 16/285 (5.6) 3/127 (2.4) 13/101 (12.9) 0.003 
Fine motor disturbance/ tremor/ writing alteration  16/285 (5.6) 3/127 (2.4) 9/101 (8.9) 0.03 
Incoordination/ clumsiness 13/285 (4.6) 6/127 (4.7) 7/101 (6.9) > 0.05 
 
All relevant information was not available or extractable for every case hence the variable numbers. Similar clinical features described in 
different ways in different articles have been combined into single sections for clarity: for example, ‘seizures’ and ‘epilepsy’. Some individuals 
with JHD presented with multiple clinical features, up to a maximum of four, all of which are included in the table. Presenting characteristics 
found in fewer than 10 cases of JHD were not included in the table. These were swallowing disturbance/sialorrhoea (9), substance misuse (8), 
psychosis (3), binge eating (1) and oculomotor abnormalities (1). The p values in the right column are derived from Fisher’s exact test of the 
null hypothesis that there is no significant difference between the prevalence of individual features in childhood and adolescent onset JHD. 
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Figure Legends 
Figure 1. Flow diagram displaying the search strategy employed and the article inclusion and 
exclusion process. In total, 79 studies were included in the final collation for analysis. 
Figure 2. Baseline characteristics of cases included in this review. A. Sex and parental source of 
expanded CAG repeat. B. Comparison of the sex and parental source of the expanded CAG repeat 
between childhood-onset (age 0-10 years) and adolescent-onset (age 11-20 years) cases. C. 
Histogram showing the numbers of cases of JHD in this study presenting at each age, where data 
available (n=228). D. Scatter plot of CAG repeat length against age at onset of first symptoms or 
signs of JHD for cases where data available (n=154). 
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Figure 1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The search terms used in the 
‘abstract’ and ‘title’ fields were 
Huntington AND juvenile OR 
child OR early OR young OR 
paediatric OR Westphal OR 
infant using the MEDLINE and 
EMBASE databases 
Records identified by search 
strategy 
 (n=2917) 
Records screened by title and/or 
abstract  
(n=2917) 
 
Records excluded (n=2815). 
Reasons: 
- Reviews 
- Not JHD 
- Non-English 
- Non-human research 
 
Additional records identified 
through references of accessed 
full-text records (n=0) 
 
Full-text articles assessed for 
eligibility  
(n=102) 
 
Full-text articles excluded 
(n=23). Reasons:  
- Unrelated to research 
question (n=13)  
- Not able to extract 
JHD data from HD 
cohort (n=2) 
- Focus on specific 
clinical feature (n=2) 
- Review article (n=2) 
- Did not meet quality 
criteria (n=2) 
- Data reported in 
previously published 
included record (n=2) 
 
Studies included for data 
synthesis  
(n=79) 
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Supplementary Material 
Table S1. Quality assessment matrix for the 10 case series included in this study. Unsatisfactory (N) ratings in fewer than four domains permitted 
inclusion. 
Case series 
[ref] 
1. Are valid 
methods used 
for 
identification of 
the condition 
for all 
participants 
included in the 
case series? 
2. Are 
demographics of 
the participants 
clearly and fully 
described? 
3. Are the 
cases 
collected in 
more than 
one centre? 
4. Are the 
inclusion and 
exclusion 
criteria for 
entry into the 
study clearly 
stated? 
5. Were 
participants 
recruited 
consecutively? 
6. Are there 
clear reporting 
of clinical 
information of 
the 
participants? 
7. Are the 
outcomes or 
follow up 
results of 
cases clearly 
reported? 
8. If statistical 
analysis was 
performed, was 
it appropriate? 
Include 
Gatto [1] Y Y Unclear N Y Y Y Y Y 
Gonzalez- 
Alegre [2] 
Y Y N Y Y Y Y N/A Y 
Ho [3] Y N N Y Unclear Y Y N/A Y 
Koutsis [4] Y Y N Y Y Y N Y Y 
Nance [5] Y N Y N N/A Y N N/A Y 
Rasmussen 
[6] 
Y N N N Y Y Y N/A Y 
Reynolds 
[7] 
Y Y N Y Unclear Y Y N/A Y 
24 
 
Ribaï [8] Y Y N N Y Y Y Y Y 
Siesling [9] Y N Y Y Y Y Y Y Y 
Squitieri 
[10] 
Y N Y N Unclear  Y N N/A Y 
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Table S2. Quality assessment matrix for the 69 case reports included in this study. Unsatisfactory (N) ratings in fewer than three domains permitted 
inclusion. 
Case report [ref] 1. Are demographics 
of the patient clearly 
and fully described? 
2. Is the patient’s history 
clearly described and 
presented? 
3. Is the clinical condition 
of the patient on 
presentation clearly 
described? 
4. Are diagnostics tests or 
assessment methods, and 
results clearly described? 
5. Is the outcome or 
follow up of the case 
clearly reported? 
Include 
Angelini [11] Y Y Y Y N Y 
Bird [12] Y Y Y N Y Y 
Bodensteiner [13] Y Y Y Y Y Y 
Brooks [14] Y Y Y Y Y Y 
Byers [15] Y Y Y N Y Y 
Cislaghi [16] Y Y Y Y Y Y 
Chuo [17] Y Y Y Y Y Y 
Cubo [18] Y Y Y Y Y Y 
Comunale [19] Y Y Y Y N Y 
Dayananthan 
[20] 
Y Y Y Y Y Y 
Dewhurst [21] Y Y Y Y Y Y 
Duesterhus [22] Y Y Y Y Y Y 
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Findling [23] Y Y Y Y Y Y 
Gambardella [24] Y Y Y Y N Y 
Geevasinga [25] Y Y Y Y Y Y 
Gencik [26] Y Y Y Y Y Y 
Goebel [27] Y Y Y Y Y Y 
Gosk [28] Y Y Y N N Y 
Gadomska [29] Y Y Y N N Y 
Haslam [30] Y Y Y Y Y Y 
Hattori [31] Y Y Y Y N Y 
Hofgartner [32] Y Y Y Y N Y 
Holinski-Feder 
[33] 
Y Y Y Y Y Y 
Isobe [34] Y Y Y Y Y Y 
Jongen* [35] Y Y Y Y N Y 
Karagöl [36] Y Y Y Y N Y 
Katafuchi [37] Y Y Y Y Y Y 
King [38] Y Y Y N Y Y 
Koul* [39] Y Y Y N Y Y 
Krishnappa [40] Y Y Y Y Y Y 
27 
 
Landau [41] Y Y Y Y N Y 
Lenti [42] Y Y Y Y Y Y 
Levy* [43] Y Y Y Y N Y 
Liu* [44] Y Y Y Y N Y 
Lopez-
Castellanos [45] 
Y Y Y N Y Y 
Marconi [46] Y Y Y Y Y Y 
Matthews [47] Y Y Y Y Y Y 
Milunsky [48] Y Y Y Y N Y 
Monrad [49] Y Y Y Y N Y 
Nahhas [50] Y Y Y Y Y Y 
Navarrete* [51] Y Y Y Y Y Y 
Naphade [52] Y Y Y Y N Y 
Nicolas [53] Y Y Y Y N Y 
Oliver* [54] Y Y Y N N Y 
Osborne* [55] Y Y Y N Y Y 
Papapetropoulos 
[56] 
Y Y Y Y Y Y 
Patra [57] Y Y Y Y Y Y 
28 
 
Revuelta [58] Y Y Y Y Y Y 
Reyes Molón [59] Y Y Y Y Y Y 
Rodda [60] Y Y Y Y Y Y 
Rossi Sebastiano 
[61] 
N Y Y Y N Y 
Ruocco* [62] Y Y Y Y Y Y 
Saffer* [63] Y Y Y Y Y Y 
Sakazume [64] Y Y Y Y N Y 
Santos [65] Y Y Y Y Y Y 
Schapiro [66] Y Y Y Y N Y 
Scrimgeour [67] Y Y Y Y N Y 
Seneca [68] Y Y Y Y N Y 
Squitieri [69] Y Y Y Y Y Y 
Srivastava [70] Y Y Y Y N Y 
Sunwoo [71] Y Y Y Y Y Y 
Topper [72] Y Y Y Y N Y 
Toufexis* [73] Y Y Y Y N Y 
Ullrich [74] Y Y Y Y Y Y 
Vargas [75] Y Y Y Y Y Y 
29 
 
Waugh [76] Y Y Y Y Y Y 
Wojaczyńska-
Stanek [77] 
Y Y Y Y Y Y 
Xing [78] Y Y Y Y Y Y 
Yoon* [79] Y Y Y Y N Y 
*Denotes case reports with more than one subject 
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